A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
1 other identifier
observational
2,150
7 countries
71
Brief Summary
The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient population across different geographical regions.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2026
Shorter than P25 for all trials
71 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 30, 2026
CompletedStudy Start
First participant enrolled
May 6, 2026
CompletedFirst Posted
Study publicly available on registry
May 26, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 31, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 31, 2027
July 7, 2026
March 1, 2026
11 months
April 30, 2026
July 3, 2026
Conditions
Outcome Measures
Primary Outcomes (4)
Patient demographics
Summary statistics
Visit 1 (Single day)
Medical and surgical history
Summary statistics
Visit 1 (Single day)
Concomitant medication
Summary statistics
Visit 1 (Single day)
HbA1c levels
Summary statistics
Visit 1 (Single day)
Secondary Outcomes (1)
Referral to ongoing or future T2DM study.
Visit 1 (Single day)
Study Arms (1)
Participants with Type 2 Diabetes
Participants with Type 2 Diabetes
Interventions
The approximate volume of blood required is 2 mL
Eligibility Criteria
Adults with Type 2 Diabetes
You may qualify if:
- Participants must be ≥ 18 years of age at the time of signing the ICF.
- Patients with a diagnosis of T2DM, test- or documentation-confirmed as per World
- Health Organization or local diagnostic standards, inadequately managed with:
- Lifestyle management alone, AND/OR
- A stable dose of background glucose-lowering medication(s) for T2DM (As specified in the Protocol) for at least 45 days prior to signing the ICF.
- Expresses interest in participating in an ongoing or future T2DM clinical study, is motivated and willing to make themselves available for the duration of the study, and is able to follow study procedures as required.
- Provision of signed and dated written informed consent (As specified in the Protocol) before any study-specific procedures, sampling, or analysis.
You may not qualify if:
- Current or planned use of GLP-1 RAs prohibited in ongoing or future T2DM studies evaluating the efficacy and safety of investigational GLP-1 RAs (As specified in the Protocol).
- Diagnosed with Type 1 diabetes mellitus.
- Known pregnancy at the time of visit or having the intention to become pregnant.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (71)
Research Site
Little Rock, Arkansas, 72205, United States
Research Site
Lincoln, California, 95648, United States
Research Site
Lake City, Florida, 32055, United States
Research Site
Ocoee, Florida, 34761, United States
Research Site
Decatur, Georgia, 30030, United States
Research Site
El Dorado, Kansas, 67042, United States
Research Site
Potomac, Maryland, 20854, United States
Research Site
Gaffney, South Carolina, 29340, United States
Research Site
Renton, Washington, 98057, United States
Research Site
Fortaleza, Ceará, 60430-350, Brazil
Research Site
Curitiba, Paraná, 80030-480, Brazil
Research Site
Natal, Rio Grande do Norte, 59020-035, Brazil
Research Site
Porto Alegre, Rio Grande do Sul, 90630-165, Brazil
Research Site
Campinas, S O Paulo, 13060-904, Brazil
Research Site
São José dos Campos, S O Paulo, 12243-280, Brazil
Research Site
São Paulo, São Paulo, 01228-200, Brazil
Research Site
São Paulo, São Paulo, 04012-180, Brazil
Research Site
Barretos, 14784-400, Brazil
Research Site
Brasília, 71625-009, Brazil
Research Site
Rio de Janeiro, 22270-060, Brazil
Research Site
Budapest, HU, 1036, Hungary
Research Site
Budapest, HU, 1089, Hungary
Research Site
Debrecen, HU, 4032, Hungary
Research Site
Szeged, HU, 6725, Hungary
Research Site
Budapest, 1024, Hungary
Research Site
Budapest, 1132, Hungary
Research Site
Budapest, 1138, Hungary
Research Site
Salgótarján, 3100, Hungary
Research Site
Szolnok, 5000, Hungary
Research Site
Zalaegerszeg, 8900, Hungary
Research Site
Guntur, Andhra Pradesh, 522001, India
Research Site
Guwahati, Assam, 781032, India
Research Site
Bangalore, Karnataka, 560092, India
Research Site
Belagavi, Karnataka, 590006, India
Research Site
Belagavi, Karnataka, 590010, India
Research Site
Calicut, Kerala, 673008, India
Research Site
Kochi, Kerala, 682041, India
Research Site
Thiruvananthapuram, Kerala, 695031, India
Research Site
Indore, Madhya Pradesh, 452008, India
Research Site
Mumbai, Maharashtra, 400012, India
Research Site
Nagpur, Maharashtra, 440010, India
Research Site
Pune, Maharashtra, 411013, India
Research Site
Pune, Maharashtra, 411021, India
Research Site
Delhi, New Delhi, 110029, India
Research Site
Jaipur, Rajasthan, 302017, India
Research Site
Chennai, Tamil Nadu, 600086, India
Research Site
Coimbatore, Tamil Nadu, 641018, India
Research Site
Lucknow, Uttar Pradesh, 226030, India
Research Site
Kolkata, West Bengal, 700020, India
Research Site
Seremban, Negeri Sembilan, 70300, Malaysia
Research Site
Seri Manjung, Perak, 32040, Malaysia
Research Site
Batu Caves, Selangor, 68100, Malaysia
Research Site
Kuala Lumpur, Wilayah Persekutuan Kuala Lump, 59100, Malaysia
Research Site
Putrajaya, 62250, Malaysia
Research Site
L Dz, L Dzkie, 90-338, Poland
Research Site
Lublin, Lublin Voivodeship, 20-718, Poland
Research Site
Krakow, Malopolska, 31-261, Poland
Research Site
Radom, Masovian Voivodeship, 26-600, Poland
Research Site
Bialystok, Podlaskie Voivodeship, 15-879, Poland
Research Site
Częstochowa, Silesian Voivodeship, 42-217, Poland
Research Site
Poznnn, 60-354, Poland
Research Site
Warsaw, 00-124, Poland
Research Site
Kielce, Świętokrzyskie Voivodeship, 25-355, Poland
Research Site
Ankara, Turkey, 6100, Turkey (Türkiye)
Research Site
Adana, 01060, Turkey (Türkiye)
Research Site
Adana, 01250, Turkey (Türkiye)
Research Site
Ankara, 06530, Turkey (Türkiye)
Research Site
Gaziantep, 27470, Turkey (Türkiye)
Research Site
Istanbul, 34265, Turkey (Türkiye)
Research Site
Istanbul, 34384, Turkey (Türkiye)
Research Site
Kayseri, 38039, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
AstraZeneca Clinical Study Information Center
CONTACT
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 1 Day
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 30, 2026
First Posted
May 26, 2026
Study Start
May 6, 2026
Primary Completion (Estimated)
March 31, 2027
Study Completion (Estimated)
March 31, 2027
Last Updated
July 7, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will share
- Time Frame
- AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
- Access Criteria
- When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.